NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
July 29, 2022 at 06:18 am EDT
Share
NanHua Bio-medicine Co., Ltd reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 104.11 million compared to CNY 67.4 million a year ago. Revenue was CNY 109.78 million compared to CNY 67.4 million a year ago. Net income was CNY 2.17 million compared to net loss of CNY 6.3 million a year ago. Basic earnings per share from continuing operations was CNY 0.007 compared to basic loss per share from continuing operations of CNY 0.0202 a year ago. Diluted earnings per share from continuing operations was CNY 0.007 compared to diluted loss per share from continuing operations of CNY 0.0202 a year ago.
Landfar Bio medicine Co Ltd is a China-based company mainly engaged in the biomedical and energy conservation & environmental protection business. The Companyâs biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Companyâs energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The Company is involved in other businesses related to aid and build project. The Company mainly conducts businesses within the domestic market.